Page 34 - Read Online

Lee Cell-mediated immunotherapy for HCC

Conflicts of interest vaccines. Immunity 2013;39:38-48.
There are no conflicts of interest. 15. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents
for the treatment of patients with cancer. Ann Surg 1997;226:1-5.
16. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor
Patient consent immune responses. I. Defective antigen presentation in tumor-bearing
Not applicable. hosts. Cell Immunol 1996;170:101-10.
17. Tarte K, Klein B. Dendritic cell-based vaccine: a promising approach
for cancer immunotherapy. Leukemia 1999;13:653-63.
Ethics approval 18. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as
Not applicable. initiators of tumor immune responses: a possible of tumor immune
strategy for tumor immunotherapy. Immunol Today 1995;16:117-21.
REFERENCES 19. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B,
Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma
using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-
1. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, 8.
Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin
S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, 20. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg
G, Schadendorf D. Vaccination of melanoma patients with peptide- or
Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A; World
tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
Gastroenterology Organization. Hepatocellular carcinoma (HCC): a 21. Höltl L, Rieser C, Papesh C, Ramoner R, Bartsch G, Thurnher M.
global perspective. J Clin Gastroenterol 2010;44:239-45.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, CD83+ blood dendritic cells as a vaccine for immunotherapy of
metastatic renal-cell cancer. Lancet 1998;352:1358.
Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver
transplantation for the treatment of small hepatocellularcarcinomas in 22. Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the
treatment of prostate cancer. Nat Rev Clin Oncol 2011;8:551-61.
patients with cirrhosis. N Engl J Med 1996;334:693-9.
3. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher 23. Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik
A, Junkmann J, Jakl V, Kiefl R, Oduncu F, Emmerich B, Mayr D,
NL, Roberts JP. Liver transplantation for hepatocellular carcinoma:
expansion of the tumor size limits does not adversely impact survival. Mussack T, Bruns C, Rüttinger D, Conrad C, Jauch KW, Endres S,
Eigler A. Dendritic cell-based vaccination of patients with advanced
Hepatology 2001;33:1394-403.
4. Lee WC, Lee CF, Cheng CH, Wu TJ, Chou HS, Wu TH, Soong pancreatic carcinoma: results of a pilot study. Cancer Immunol
Immunother 2011;60:1097-107.
RS, Chan KM, Yu MC, Chen MF. Outcomes of liver resection for
hepatocellular carcinoma in liver transplantation era. Eur J Surg 24. Tarte K, Klein B. Dendritic cell-based vaccine: a promising approach
for cancer immunotherapy. Leukemia 1999;13:653-63.
Oncol 2015;41:1144-52.
5. Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma 25. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF.
Vaccination of advanced hepatocellular carcinoma patients with
M, Owen R. Locoregional radiological treatment for hepatocellular
carcinoma; which, when and how? Cancer Treat Rev 2012;38:54-62. tumor lysate-pulsed dendritic cells: a clinical trial. J Immunither
2005;28:496-504.
6. Ray CE Jr, Haskal ZJ, Geschwind JF, Funaki BS. The use of 26. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin
transarterial chemoembolization in the treatment of unresectable Immunol 2007;19:217-23.
hepatocellular carcinoma: a response to the Cochrane Collaboration 27. Lee WC, Wu TJ, Chou HS, Yu MC, Hsu PY, Hsu HY, Wang CC. The
review of 2011. J Vasc Interv Radiol 2011;22:1693-6. impact of CD4+CD25+ T cells in the tumor microenvironment of
7. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, hepatocellular carcinoma. Surgery 2012;151:213-22.
Lencioni R. Evolving strategies for the management of intermediate- 28. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work.
stage hepatocellular carcinoma: available evidence and expert opinion Nat Rev Immunol 2008;8:523-32.
on the use of transarterial chemoembolization. Cancer Treat Rev 29. Huang CH, Hou YC, Pai MH, Yeh CL, Yeh SL. Dietary omega-6/
2011;37:212-20. omega-3 polyunsaturated fatty acid ratios affect the homeostasis of
8. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Th/Treg cells in mice with dextran sulfate sodium-induced colitis.
Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, JPEN J Parenter Enteral Nutr 2017;41:647-56.
Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib 30. Chen X, Du Y, Lin X, Qian Y, Zhou T, Huang Z. CD4+CD25+
in patients in the Asia-Pacific region with advanced hepatocellular regulatory T cells in tumor immunity. Int Immunopharmacol
carcinoma: a phase III randomised, double-blind, placebo-controlled 2016;34:244-9.
trial. Lancet Oncol 2009;10:25-34. 31. Kindlund B, Sjöling Å, Yakkala C, Adamsson J, Janzon A, Hansson LE,
9. Kudo M. Molecular targeted therapy for hepatocellular carcinoma: Hermansson M, Janson P, Winqvist O, Lundin SB. CD4+ regulatory T
bench to bedside. Dig Dis 2011;29:273-7. cells in gastric cancer mucosa are proliferating and express high levels
10. Ling TC, Kang JI, Bush DA, Slater JD, Yang GY. Proton therapy for of IL-10 but little TGF-beta. Gastric Cancer 2017;20:116-25.
hepatocellular carcinoma. Chin J Cancer Res 2012;24:367-73. 32. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang
11. Ishikawa T. Chemotherapy with enteric-coated tegafur/uracil FM, Ge HL, Xu D. CD4(+)CD25(+)CD127(low/-) regulatory T cells
for advanced hepatocellular carcinoma. World J Gastroenterol express Foxp3 and suppress effector T cell proliferation and contribute
2008;14:2797-801. to gastric cancers progression. Clin Immunol 2009;131:109-18.
12. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging 33. Xu T, Duan Q, Wang G, Hu B. CD4 + CD25high regulatory T cell
and treatment: the BCLC update and future prospects. Semin Liver Dis numbers and FOXP3 mRNA expression in patients with advanced
2010;30:61-74. esophageal cancer before and after chemotherapy. Cell Biochem
13. Kurkjian C, Kummar S, Murgo AJ. DNA methylation: its role in Biophys 2011;61:389-92.
cancer development and therapy. Curr Probl Cancer 2008;32:187- 34. Kim S, Lee A, Lim W, Park S, Cho MS, Koo H, Moon BI, Sung SH.
235. Zonal difference and prognostic significance of foxp3 regulatory T
14. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer cell infiltration in breast cancer. J Breast Cancer 2014;17:8-17.
248 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ October 31, 2017